CVE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free TAK Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume143,897 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Takeda Pharmaceutical alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Takeda Pharmaceutical Stock (CVE:TAK)The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. TAK Stock News HeadlinesApril 26, 2024 | lse.co.ukHutchmed notes CHMP's positive opinion for fruiquintinib approvalApril 25, 2024 | seekingalpha.comNeurocrine: Success Continues To Roll In With Positive MDD Treatment DataMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.April 24, 2024 | finance.yahoo.comAAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meetingApril 23, 2024 | msn.comNeurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive DisorderApril 23, 2024 | msn.comNeurocrine succeeds in mid-stage trial for Takeda-partnered depression drugApril 23, 2024 | finance.yahoo.comTakeda Pharmaceutical: A Long-Term Cash CowApril 22, 2024 | msn.comTop pharmaceutical company evaluates Optimer for precision liver medicineMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.April 18, 2024 | investing.comFDA approves Takeda's ENTYVIO for Crohn's diseaseApril 18, 2024 | markets.businessinsider.comFDA Approves Subcutaneous Administration Of Takeda's Entyvio For Crohn's DiseaseApril 18, 2024 | marketwatch.comTakeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's DiseaseApril 18, 2024 | finance.yahoo.comTakeda Pharmaceutical Company Limited (TKD.VI)April 15, 2024 | seekingalpha.comJazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay OffApril 12, 2024 | bizjournals.comViewpoint: To stay on top, Boston must lead pharma’s transformationApril 11, 2024 | benzinga.comAssessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals IndustryApril 3, 2024 | stockhouse.comLigand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI(TM)March 30, 2024 | msn.comThis could be the worst year yet for dengue in the AmericasMarch 27, 2024 | finance.yahoo.comEphicacy Bolsters Leadership Team with Four New HiresMarch 27, 2024 | finanznachrichten.deTakeda Pharmaceuticals: Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEMarch 20, 2024 | markets.businessinsider.comScilex, Takeda Settle Paragraph IV Patent Infringement Lawsuit - Quick FactsMarch 13, 2024 | markets.businessinsider.comTakeda: Mezagitamab Phase 2 Trial Shows Positive Results In Primary Immune ThrombocytopeniaMarch 13, 2024 | msn.comUniversity Of Strathclyde Invites Applications For MSc Advanced Pharmaceutical Manufacturing Course Starting September 2024February 28, 2024 | finance.yahoo.comTakeda Pharmaceutical Co Ltd (TKD.HM)February 28, 2024 | msn.comTakeda and Biological E partner to boost dengue vaccine production in IndiaFebruary 27, 2024 | finance.yahoo.comCholera Vaccines Market to Reach USD 167.3 Million by 2030, Fueled by a CAGR of 9.0% from 2030 | MarketDigitsFebruary 27, 2024 | sg.finance.yahoo.comTakeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.See More Headlines Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorManufacturing Industry Medicinal & Botanical Manufacturing Sub-IndustryN/A Current SymbolCVE:TAK CUSIPN/A CIKN/A Webwww.takugold.com Phone+1-604-6420115FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesGilles DessureauInterim PresidentGregory Donald HayesInterim Chief Financial Officer, Corporate SecretaryPeter BuresDirectorDennis Gordon FentieDirectorJanet Lee-SheriffDirectorLori WaltonDirectorC.F. Wasser IIIDirectorMore ExecutivesKey CompetitorsHigh TideTSE:HITINovus EnergyCVE:NVS(EDW.V)CVE:EDW(FSN.V)CVE:FSN(FTE.V)CVE:FTEView All Competitors TAK Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Pure Gold Mining (PGM), Valhi (VHI) and Fission Uranium (FCUUF). How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:TAK) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTracker Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
